<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20250306091105&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20250306091105&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 06 Mar 2025 14:11:06 +0000</lastbuilddate>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>LncRNA MIR181A1HG Deficiency Attenuates Vascular Inflammation and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify MIR181A1HG as a central driver of vascular inflammation in atherosclerosis by its ability to decoy Foxp1 away from target gene promoters and activate NLRP3 inflammasome in the vascular endothelium. Our study suggests MIR181A1HG as a future therapeutic target for vascular inflammatory disease states.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 6. doi: 10.1161/CIRCRESAHA.124.325196. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Endothelial cell (EC) dysfunction and vascular inflammation are critical in the initiation and progression of atherosclerosis. Long noncoding RNAs play a critical role in vascular pathology, but relatively little is known about their involvement in controlling vascular inflammation. MIR181A1HG is a conserved long noncoding RNA located in juxtaposition with miR-181a1 and miR-181b1, both involved in vascular inflammation. The study aims to investigate the role of MIR181A1HG in regulating vascular inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined the expression of MIR181A1HG in both human and mouse atherosclerotic lesions. Loss-of-function and gain-of-function studies, and multiple RNA-protein interaction assays were used to investigate the role and molecular mechanisms of MIR181A1HG in vascular inflammation and atherosclerosis. The atherosclerotic phenotypes of MIR181A1HG<sup>-/-</sup>ApoE<sup>-/-</sup> mice were analyzed in combination with single-cell RNA sequencing. The transcriptional regulation of MIR181A1HG was verified through luciferase reporter and chromatin immunoprecipitation assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: MIR181A1HG expression was abundant in ECs and significantly increased in both human and mouse atherosclerotic lesions. MIR181A1HG<sup>-/-</sup>ApoE<sup>-/-</sup> mice had reduced NLRP (NLR family pyrin domain containing) 3 inflammasome signaling, EC activation, monocyte infiltration, and atherosclerotic lesion formation. Genetic deletion of MIR181A1HG in myeloid sells did not alter the progression of atherosclerosis. Single-cell RNA sequencing analysis revealed that MIR181A1HG deficiency reduced the proportion of immune cells and enriched anti-inflammation pathways in EC clusters in atherosclerotic lesions. In contrast, EC-specific MIR181A1HG overexpression promoted NLRP3 inflammasome signaling, EC activation, and atherosclerotic lesion formation, effects that were reversed by pharmacological inhibition of NLRP3 (MCC950). MIR181A1HG was transcriptionally activated via an NF-κB (nuclear factor kappa B)/p65-dependent pathway. Mechanistically, MIR181A1HG mediated these effects on regulating NLRP3 inflammasome and EC activation in part through decoying Foxp1 (forkhead box transcription factor 1) away from the promoters of target genes, which was independent of the miR-181a1/b1 cluster. Finally, EC-specific Foxp1 silencing reversed the antiatherosclerotic effect mediated by MIR181A1HG-deletion in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify MIR181A1HG as a central driver of vascular inflammation in atherosclerosis by its ability to decoy Foxp1 away from target gene promoters and activate NLRP3 inflammasome in the vascular endothelium. Our study suggests MIR181A1HG as a future therapeutic target for vascular inflammatory disease states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40047069</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325196>10.1161/CIRCRESAHA.124.325196</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40047069</guid>
<pubDate>Thu, 06 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Huaner Ni</dc:creator>
<dc:creator>Yulong Ge</dc:creator>
<dc:creator>Ying Zhuge</dc:creator>
<dc:creator>Xiaoqiang Liu</dc:creator>
<dc:creator>Hangwei Chen</dc:creator>
<dc:creator>Junyi Liu</dc:creator>
<dc:creator>Weifeng Li</dc:creator>
<dc:creator>Xiang Wang</dc:creator>
<dc:creator>Gu Shen</dc:creator>
<dc:creator>Qiuling Wang</dc:creator>
<dc:creator>Rulin Zhuang</dc:creator>
<dc:creator>Mark W Feinberg</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:date>2025-03-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>LncRNA MIR181A1HG Deficiency Attenuates Vascular Inflammation and Atherosclerosis</dc:title>
<dc:identifier>pmid:40047069</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325196</dc:identifier>
</item>
<item>
<title>Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40045042/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>Communication between multicellular organs is essential to propagate signals and coordinate their function. Over the past decade, the role of extracellular vesicles in the molecular communication between cells in both physiological and pathological settings has received much attention. Extracellular vesicles can shuttle proteins, lipids and nucleic acids (such as RNA) between cells, thus inducing an array of functional changes in the recipient cells. In this Review, we describe the different...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 5. doi: 10.1038/s41569-025-01141-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Communication between multicellular organs is essential to propagate signals and coordinate their function. Over the past decade, the role of extracellular vesicles in the molecular communication between cells in both physiological and pathological settings has received much attention. Extracellular vesicles can shuttle proteins, lipids and nucleic acids (such as RNA) between cells, thus inducing an array of functional changes in the recipient cells. In this Review, we describe the different extracellular vesicle subclasses and their heterogeneous nature, provide insights into extracellular vesicle-mediated signalling in the cardiovascular system, and highlight how extracellular vesicles can be used as diagnostic and prognostic biomarkers for a variety of pathological conditions. Finally, we also discuss the potential therapeutic applications of extracellular vesicles.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40045042/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40045042</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01141-2>10.1038/s41569-025-01141-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40045042</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Junjie Xiao</dc:creator>
<dc:creator>Joost P G Sluijter</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy</dc:title>
<dc:identifier>pmid:40045042</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01141-2</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):968-969. doi: 10.1016/j.jacc.2025.01.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044301</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.003>10.1016/j.jacc.2025.01.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044301</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:40044301</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.003</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044300/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):967-968. doi: 10.1016/j.jacc.2025.01.010.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044300/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044300</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.010>10.1016/j.jacc.2025.01.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044300</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:40044300</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.010</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044299/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>Transcatheter aortic valve replacement (TAVR) has become the preferred treatment option in appropriate patients with symptomatic severe aortic stenosis (AS). A number of advancements have since expanded the eligible population to bicuspid aortic valve with feasible anatomy; small aortic annuli; low-flow, low-gradient AS; and younger patients. Focus has also shifted beyond the symptomatic severe patients to asymptomatic severe and moderate AS, as early valve replacement may prevent irreversible...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):944-964. doi: 10.1016/j.jacc.2024.11.051.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcatheter aortic valve replacement (TAVR) has become the preferred treatment option in appropriate patients with symptomatic severe aortic stenosis (AS). A number of advancements have since expanded the eligible population to bicuspid aortic valve with feasible anatomy; small aortic annuli; low-flow, low-gradient AS; and younger patients. Focus has also shifted beyond the symptomatic severe patients to asymptomatic severe and moderate AS, as early valve replacement may prevent irreversible cardiac remodeling. Dedicated devices to treat native aortic regurgitation have shown encouraging short-term outcomes. While the expansion of TAVR to younger patients has raised questions about valve durability and feasibility of reintervention, valve-in-valve TAVR has thus far shown encouraging midterm results. In this review, we summarize the evidence in these contemporary TAVR populations, exploring both the promise and challenge of broadening the patient pool for this minimally invasive procedure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044299/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044299</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.051>10.1016/j.jacc.2024.11.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044299</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Frans J Beerkens</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Annapoorna S Kini</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Sahil Khera</dc:creator>
<dc:creator>Martin Goldman</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>John G Webb</dc:creator>
<dc:creator>Samin K Sharma</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:40044299</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.051</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes of Transcatheter vs Surgical Aortic Valve Replacement for Lower-Risk Patients: Are We There Yet?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044298/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):941-943. doi: 10.1016/j.jacc.2025.01.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044298</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.020>10.1016/j.jacc.2025.01.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044298</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Joshua D Wallach</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcomes of Transcatheter vs Surgical Aortic Valve Replacement for Lower-Risk Patients: Are We There Yet?</dc:title>
<dc:identifier>pmid:40044298</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.020</dc:identifier>
</item>
<item>
<title>Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In lower-risk patients, TAVR was associated with a reduced hazard of death and death or disabling stroke compared with SAVR, while rates of stroke were equivalent. Most patients have not yet undergone 5-year follow-up, and so these findings may change as further longer-term data become available. The present data are informative for lower-risk patients and treating clinicians, but further randomized trials and longer-term follow-up are required, particularly in younger patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):926-940. doi: 10.1016/j.jacc.2024.12.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Longer-term outcomes are especially important for lower-risk patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Additional randomized data comparing TAVR and SAVR have recently become available.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to perform an updated systematic review with conventional pairwise meta-analyses and pooled survival analyses using reconstructed time-to-event individual participant data (IPD) including the totality of randomized evidence comparing longer-term clinical outcomes after TAVR and SAVR in lower-risk patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The prespecified primary endpoint was all-cause death. Key secondary endpoints included stroke and the composite of death or disabling stroke. Cox proportional hazards frailty regression and restricted mean survival time models were fitted using reconstructed time-to-event IPD. In sensitivity analyses, proportional odds models were fitted with frailty terms. Conventional pairwise meta-analyses were performed under random and fixed effects assumptions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Six trials enrolling 5,341 lower-risk patients were included with 2,717 randomized to TAVR and 2,624 randomized to SAVR (weighted mean follow-up of 35.7 months). At 5 years in the pooled survival analyses of reconstructed time-to-event IPD, TAVR was associated with a 20% reduction in the hazard of all-cause death (HR: 0.80; 95% CI: 0.66-0.97; P = 0.02) and a 19% reduction in the hazard of all-cause death or disabling stroke (HR: 0.81; 95% CI: 0.68-0.96; P = 0.01) compared with SAVR. There was no difference in stroke (HR: 0.97; 95% CI: 0.74-1.26; P = 0.80).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In lower-risk patients, TAVR was associated with a reduced hazard of death and death or disabling stroke compared with SAVR, while rates of stroke were equivalent. Most patients have not yet undergone 5-year follow-up, and so these findings may change as further longer-term data become available. The present data are informative for lower-risk patients and treating clinicians, but further randomized trials and longer-term follow-up are required, particularly in younger patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044297</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.031>10.1016/j.jacc.2024.12.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044297</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Rohin K Reddy</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>William D Toff</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Amit N Vora</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Samir Kapadia</dc:creator>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials</dc:title>
<dc:identifier>pmid:40044297</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.031</dc:identifier>
</item>
<item>
<title>Navigating the Landscape of Reinterventions After TAVR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):908-911. doi: 10.1016/j.jacc.2024.12.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044296</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.018>10.1016/j.jacc.2024.12.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044296</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Syed Zaid</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Navigating the Landscape of Reinterventions After TAVR</dc:title>
<dc:identifier>pmid:40044296</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.018</dc:identifier>
</item>
<item>
<title>Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Reintervention after TAVR remains rare and was mostly performed early after the procedure and by redo TAVR. Further studies are warranted, particularly in younger patients with longer life expectancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):896-907. doi: 10.1016/j.jacc.2024.11.048.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In a context of extending transcatheter aortic valve replacement (TAVR) to patients with a longer life expectancy, it is important to better document the incidence and outcomes of reintervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to evaluate the incidence, predictive factors, and long-term outcomes of surgical (explant TAVR) or transcatheter (redo TAVR) reintervention after TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients who had a TAVR between 2010 and 2022 recorded in the FRANCE 2 and FRANCE TAVI registries were included in the analysis. Cumulative incidence of early (≤1 year) and late (>;1 year) reintervention was assessed using the Kalbfleisch and Prentice method to account for all-cause death as a competing risk. Patients who had reintervention for infective endocarditis were excluded. Long-term mortality was evaluated using Kaplan-Meier analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 72,850 patients included, the cumulative incidence of overall reintervention at 8 years was 1.7% including 591 patients who had redo TAVR and 111 patients who required explant TAVR with a low incidence of Bentall intervention. Reintervention occurred mostly early in 62.1% of cases and was more frequent in patients who had a mean aortic gradient >;20 mm Hg immediately after index TAVR. Age and mean aortic gradient before TAVR and mean aortic gradient >;20 mm Hg, aortic regurgitation ≥ grade 2, and percutaneous coronary intervention after TAVR were predictive of reintervention. Six-year mortality was high but was similar in patients who had early and late reintervention (76.2% vs 64.0%; P = 0.77).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Reintervention after TAVR remains rare and was mostly performed early after the procedure and by redo TAVR. Further studies are warranted, particularly in younger patients with longer life expectancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044295</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.048>10.1016/j.jacc.2024.11.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044295</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Eric Durand</dc:creator>
<dc:creator>Hélène Eltchaninoff</dc:creator>
<dc:creator>Didier Tchetche</dc:creator>
<dc:creator>Thomas Levesque</dc:creator>
<dc:creator>Christian Garmendia</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Hakim Benamer</dc:creator>
<dc:creator>Guillaume Cayla</dc:creator>
<dc:creator>Eric Van Belle</dc:creator>
<dc:creator>Philippe Commeau</dc:creator>
<dc:creator>Herve Le Breton</dc:creator>
<dc:creator>Thomas Cuisset</dc:creator>
<dc:creator>Mariama Akodad</dc:creator>
<dc:creator>Jean-Philippe Verhoye</dc:creator>
<dc:creator>Sylvain Beurtheret</dc:creator>
<dc:creator>Florence du Chayla</dc:creator>
<dc:creator>Manon Leclere</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Nicolas Dumonteil</dc:creator>
<dc:creator>STOP-AS and France TAVI Investigators</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries</dc:title>
<dc:identifier>pmid:40044295</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.048</dc:identifier>
</item>
<item>
<title>The Evolving Landscape of TAVR: A JACC Themed Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40044294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11;85(9):875-877. doi: 10.1016/j.jacc.2025.01.021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40044294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40044294</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.021>10.1016/j.jacc.2025.01.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40044294</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Evolving Landscape of TAVR: A JACC Themed Issue</dc:title>
<dc:identifier>pmid:40044294</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.021</dc:identifier>
</item>
<item>
<title>Mapping the landscape of social behavior</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40043703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>Social interaction is integral to animal behavior. However, lacking tools to describe it in quantitative and rigorous ways has limited our understanding of its structure, underlying principles, and the neuropsychiatric disorders, like autism, that perturb it. Here, we present a technique for high-resolution 3D tracking of postural dynamics and social touch in freely interacting animals, solving the challenging subject occlusion and part-assignment problems using 3D geometric reasoning, graph...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 28:S0092-8674(25)00154-0. doi: 10.1016/j.cell.2025.01.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Social interaction is integral to animal behavior. However, lacking tools to describe it in quantitative and rigorous ways has limited our understanding of its structure, underlying principles, and the neuropsychiatric disorders, like autism, that perturb it. Here, we present a technique for high-resolution 3D tracking of postural dynamics and social touch in freely interacting animals, solving the challenging subject occlusion and part-assignment problems using 3D geometric reasoning, graph neural networks, and semi-supervised learning. We collected over 110 million 3D pose samples in interacting rats and mice, including seven monogenic autism rat lines. Using a multi-scale embedding approach, we identified a rich landscape of stereotyped actions, interactions, synchrony, and body contacts. This high-resolution phenotyping revealed a spectrum of changes in autism models and in response to amphetamine not resolved by conventional measurements. Our framework and large library of interactions will facilitate studies of social behaviors and their neurobiological underpinnings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40043703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40043703</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.044>10.1016/j.cell.2025.01.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40043703</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Ugne Klibaite</dc:creator>
<dc:creator>Tianqing Li</dc:creator>
<dc:creator>Diego Aldarondo</dc:creator>
<dc:creator>Jumana F Akoad</dc:creator>
<dc:creator>Bence P Ölveczky</dc:creator>
<dc:creator>Timothy W Dunn</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mapping the landscape of social behavior</dc:title>
<dc:identifier>pmid:40043703</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.044</dc:identifier>
</item>
<item>
<title>Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0410. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042967</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0410>10.1001/jamacardio.2025.0410</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042967</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael J Blaha</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy</dc:title>
<dc:identifier>pmid:40042967</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0410</dc:identifier>
</item>
<item>
<title>Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To validate the Prognostic Models for Mortality and Morbidity in HFpEF (PREDICT-HFpEF) in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) and to evaluate the effect of finerenone, compared with placebo, across the spectrum of risk in these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The FINEARTS-HF trial was conducted across 653 sites in 37 countries. Participants were adults 40 years and older with symptomatic HF and left ventricular EF of 40% or greater randomized between September 2020 and January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The 3 PREDICT-HFpEF risk scores for the composite outcome of cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death, respectively, were calculated. Predicted risk was compared with observed outcomes. Model performance was assessed using the Harrell C statistic. The rates of the predicted outcomes (plus the composite of cardiovascular death and worsening HF events, which was the primary end point in the trial) were examined according to quintiles of risk score, as was the effect of finerenone according to risk quintiles.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6001 patients (mean [SD] age, 72 [9.6] years; 3269 male [54.5%]) were randomized in the FINEARTS-HF trial. The C statistics for cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death at 2 years were 0.71 (95% CI, 0.69-0.72), 0.68 (95% CI, 0.66-0.71), and 0.69 (95% CI, 0.67-0.71), respectively. The risk of the composite outcomes was approximately 8- to 10-fold higher in those in the highest compared with the lowest risk quintile. The relative risk reduction with finerenone compared with placebo was consistent across the spectrum of risk for all outcomes examined (eg, interaction P value for primary outcome = .24).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042880</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0025>10.1001/jamacardio.2025.0025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042880</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Kirsty McDowell</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Ross T Campbell</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Lucas Hofmeister</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF</dc:title>
<dc:identifier>pmid:40042880</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0025</dc:identifier>
</item>
<item>
<title>Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042835/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0038. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042835</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0038>10.1001/jamacardio.2025.0038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042835</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:40042835</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0038</dc:identifier>
</item>
<item>
<title>Importance of Age and Sex in Carotid Artery Plaque Detection and Cardiovascular Disease Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: CAP becomes very common with increasing age among individuals without clinical ASCVD, and the association of CAP with incident ASCVD events was strongest in younger ages, especially among women. These data can help guide ASCVD risk assessment in younger adults and provide perspective when CAP is detected on clinical imaging studies in older adults.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2024.5702. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Carotid artery plaque (CAP) is commonly encountered in clinical practice. Presence of CAP predicts future atherosclerotic cardiovascular disease (ASCVD) events; however, CAP prevalence increases with age, and it is unknown how age and sex affect the association of CAP presence and ASCVD risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To describe CAP prevalence by age, sex, race, and ethnicity in a multiethnic population and to investigate whether the impact of CAP detection on relative ASCVD risk declines with age and differs by sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study examines participants in the Multi-Ethnic Study of Atherosclerosis (MESA). Adults aged 45 to 84 years who were free of clinical ASCVD at recruitment (2000-2002) were included, and follow-up for ASCVD events was conducted through December 2019. Data analysis was performed from July 2023 to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Presence of CAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was ASCVD events (coronary heart disease events, stroke, and ASCVD death). Prevalence of CAP by age, sex, race, and ethnicity was calculated. Cox proportional hazards models with age interaction terms were used to investigate associations of CAP and incident ASCVD events across sexes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6814 adults in the MESA cohort, 5689 participants had complete data and were included in this analysis. Among these 5689 participants, mean (SD) age was 62.0 (10.2) years, and 3002 participants (53%) were female. The cohort included 1551 Black participants (27%), 687 Chinese participants (12%), 1276 Hispanic participants (22%), and 2165 White participants (38%). In total, participants experienced 1043 ASCVD events over a median (IQR) period of 17.6 (10.5-18.4) years. Prevalence of CAP differed by age, sex, race, and ethnicity, ranging from 15% in Chinese women younger than 50 years to 95% in non-Hispanic White men aged 80 to 84 years. CAP independently predicted ASCVD events (hazard ratio, 1.38; 95% CI, 1.20-1.58; P &lt; .001). The strength of this association was stronger among younger participants (≤60 years) vs older (>;60 years) (P for interaction = .01), especially among women (P for interaction = .005) vs men (P for interaction = .66). CAP detection in younger individuals conferred higher relative ASCVD risk than in older participants, who had higher absolute risk regardless of CAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: CAP becomes very common with increasing age among individuals without clinical ASCVD, and the association of CAP with incident ASCVD events was strongest in younger ages, especially among women. These data can help guide ASCVD risk assessment in younger adults and provide perspective when CAP is detected on clinical imaging studies in older adults.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042830</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5702>10.1001/jamacardio.2024.5702</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042830</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew C Tattersall</dc:creator>
<dc:creator>Spencer L Hansen</dc:creator>
<dc:creator>Robyn L McClelland</dc:creator>
<dc:creator>Claudia E Korcarz</dc:creator>
<dc:creator>Kristin M Hansen</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>James H Stein</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Age and Sex in Carotid Artery Plaque Detection and Cardiovascular Disease Risk</dc:title>
<dc:identifier>pmid:40042830</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5702</dc:identifier>
</item>
<item>
<title>Error in Abstract and Visual Abstract</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0396. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042829</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0396>10.1001/jamacardio.2025.0396</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042829</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Abstract and Visual Abstract</dc:title>
<dc:identifier>pmid:40042829</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0396</dc:identifier>
</item>
<item>
<title>Coronary Artery Calcium Testing-Too Early, Too Late, Too Often</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: These clinical scenarios reflect when consideration of CAC score is of use and when it is not. Although CAC testing is becoming more widely available and sought after by clinicians and patients alike, it is only as useful as the clinical context. Understanding when assessing CAC score is too early to effectively rule out risk, too late to influence decisions, or too often to yield clinically relevant information provides important insights that optimize the clinical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2024.5644. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Traditional risk factors, enhancing factors, and risk scores help clinicians assess atherosclerotic cardiovascular disease (ASCVD) risk for primary prevention. The latest cholesterol guidelines suggest measuring coronary artery calcium (CAC) score by computed tomography (CT) in those at intermediate risk when there is uncertainty about statin initiation for primary prevention. CAC testing can improve both risk estimation and adherence to cardiovascular risk-reducing behaviors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: As measuring CAC score has become more widely available, this article focuses on 3 situations where CAC testing may be omitted or deferred until a time when CAC testing can provide clinically useful information. Three clinical scenarios to facilitate the clinician-patient risk discussion are as follows: (1) when CAC testing is too early, (2) when CAC testing is too late, and (3) when CAC testing is repeated too often. The timing of CAC testing sits within the decision point of lipid-lowering therapy use. High-risk young adults may face an elevated lifetime risk of cardiovascular disease despite a CAC level of 0, whereas older adults may not see an expected benefit over a short time horizon or may already be taking lipid-lowering therapy, rendering a CAC score less valuable. Integrating a CAC score into the decision to initiate lipid-lowering therapy requires understanding of a patient's risk factors, including age, as well as the natural history of atherosclerosis and related events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: These clinical scenarios reflect when consideration of CAC score is of use and when it is not. Although CAC testing is becoming more widely available and sought after by clinicians and patients alike, it is only as useful as the clinical context. Understanding when assessing CAC score is too early to effectively rule out risk, too late to influence decisions, or too often to yield clinically relevant information provides important insights that optimize the clinical utility of this potentially valuable prognostic tool.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042828</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5644>10.1001/jamacardio.2024.5644</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042828</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexander R Zheutlin</dc:creator>
<dc:creator>Anuj K Chokshi</dc:creator>
<dc:creator>John T Wilkins</dc:creator>
<dc:creator>Neil J Stone</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Coronary Artery Calcium Testing-Too Early, Too Late, Too Often</dc:title>
<dc:identifier>pmid:40042828</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5644</dc:identifier>
</item>
<item>
<title>Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042824/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: These findings enhance mechanistic insights into the effect of valsartan in early-stage HCM, showing potential benefits on biventricular remodeling and myocardial intracellular volume. Further research to identify cellular mechanisms of valsartan on HCM progression is needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2024.5677. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights, but whether valsartan influences these parameters remains uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the treatment effects of valsartan on myocardial structure, function, and tissue parameters in early-stage sarcomeric HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prespecified CMR substudy of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) randomized clinical trial evaluated treatment effects of valsartan vs placebo on myocardial structure, function, and tissue parameters and was conducted from April 2014 through July 2019 at 17 international sites. Individuals aged 8 to 45 years with early-stage HCM aged between 8 and 45 years and with no or minimal symptoms were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Treatment with placebo or valsartan (80 mg per day for children weighing &lt;35 kg, 160 mg per day for children weighing ≥35 kg, or 320 mg per day for adults aged 18 years or older).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was mean change in CMR parameters between baseline and year 2, including indexed extracellular volume (iECV), indexed intracellular volume (iICV), and late gadolinium enhancement (LGE). Mean between-group differences in CMR parameters between baseline and year 2 were evaluated using multivariable mixed-effects linear regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 137 of 178 VANISH participants (77.0%) underwent CMR imaging at baseline and year 2. Among these participants, mean (SD) age was 23 (10) years, and 51 participants (37.2%) were female. Baseline characteristics and CMR parameters were well balanced between treatment groups. Higher LGE, iECV, and iICV at baseline were associated with higher cardiac biomarker levels and more pronounced cardiac remodeling. Between baseline and year 2, valsartan appeared to increase left ventricular (LV) end-diastolic volume index (mean difference [MD], 3.3 mL/m2; 95% CI, 0.4-6.2; P = .03), suggesting treatment benefit, but did not significantly impact LV mass index (MD, -2.9 g/m2; 95% CI, -6.1 to 0.2; P = .07) or LV ejection fraction. Similarly, valsartan appeared to reduce decline in right ventricular volumes. Valsartan appeared to significantly reduce iICV progression (MD, -5.0 mL/m2; 95% CI, -9.7 to -0.4; P = .03), but did not impact iECV (MD, 0.0 mL/m2; 95% CI, -1.4 to 1.3; P = .95) or LGE progression (MD, 0.5%; 95% CI, -0.4 to 1.3; P = .30).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: These findings enhance mechanistic insights into the effect of valsartan in early-stage HCM, showing potential benefits on biventricular remodeling and myocardial intracellular volume. Further research to identify cellular mechanisms of valsartan on HCM progression is needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042824/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40042824</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5677>10.1001/jamacardio.2024.5677</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042824</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Michael Jerosch-Herold</dc:creator>
<dc:creator>Anna Axelsson Raja</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Kenneth Zahka</dc:creator>
<dc:creator>Alexandre C Pereira</dc:creator>
<dc:creator>Steven D Colan</dc:creator>
<dc:creator>Anne M Murphy</dc:creator>
<dc:creator>Charles Canter</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Amit R Patel</dc:creator>
<dc:creator>Ivan Wilmot</dc:creator>
<dc:creator>Jonathan H Soslow</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Jose D Vargas</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy</dc:title>
<dc:identifier>pmid:40042824</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5677</dc:identifier>
</item>
<item>
<title>A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40038847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 5:ehaf001. doi: 10.1093/eurheartj/ehaf001. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40038847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40038847</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf001>10.1093/eurheartj/ehaf001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40038847</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexandra Butters</dc:creator>
<dc:creator>Kate Thomson</dc:creator>
<dc:creator>Franki Harrington</dc:creator>
<dc:creator>Natasha Henden</dc:creator>
<dc:creator>Karen McGuire</dc:creator>
<dc:creator>Alicia B Byrne</dc:creator>
<dc:creator>Samantha Bryen</dc:creator>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Megan Leask</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>John Atherton</dc:creator>
<dc:creator>Johan M Bos</dc:creator>
<dc:creator>Colleen Caleshu</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Kyla Dunn</dc:creator>
<dc:creator>Ian Hayes</dc:creator>
<dc:creator>Jimmy Juang</dc:creator>
<dc:creator>Julie McGaughran</dc:creator>
<dc:creator>Natalie Nowak</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Anne Ronan</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Jil C Tardiff</dc:creator>
<dc:creator>Marianne Tiemensma</dc:creator>
<dc:creator>Tony R Merriman</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Jonathan R Skinner</dc:creator>
<dc:creator>Daniel G MacArthur</dc:creator>
<dc:creator>Owen M Siggs</dc:creator>
<dc:creator>Richard D Bagnall</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets</dc:title>
<dc:identifier>pmid:40038847</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf001</dc:identifier>
</item>
<item>
<title>Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehae931. doi: 10.1093/eurheartj/ehae931. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40037651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae931>10.1093/eurheartj/ehae931</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037651</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Dick C Chan</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies</dc:title>
<dc:identifier>pmid:40037651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae931</dc:identifier>
</item>
<item>
<title>Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250306091105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093/eurheartj/ehae938. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250306091105&v=2.18.0.post9+e462414">40037646</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae938>10.1093/eurheartj/ehae938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037646</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Andrew Coats</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Martina Brueckmann</dc:creator>
<dc:creator>Sibylle J Hauske</dc:creator>
<dc:creator>Elke Schueler</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial</dc:title>
<dc:identifier>pmid:40037646</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae938</dc:identifier>
</item>





























</channel>
</rss>